- Home
- MNSB vs ABOS Comparison
MNSB vs ABOS Comparison
Compare MNSB & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | ABOS |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | 204 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.4M | 155.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNSB | ABOS |
|---|---|---|
| Price | $22.45 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 43.5K | ★ 578.2K |
| Earning Date | 04-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.00 | $0.86 |
| 52 Week High | $23.44 | $3.60 |
Technical Indicators
Market Signals| Indicator | MNSB | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 49.05 |
| Support Level | $21.76 | $1.30 |
| Resistance Level | $23.10 | $3.05 |
| Average True Range (ATR) | 0.48 | 0.26 |
| MACD | 0.09 | -0.06 |
| Stochastic Oscillator | 91.30 | 37.06 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.